Search results for "leukemia"

showing 10 items of 976 documents

Bone marrowVEGFCexpression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with sur…

2018

Vascular endothelial growth factor C (VEGFC) stimulates leukemia cell proliferation and survival, and promotes angiogenesis. We studied VEGFC expression in bone marrow samples from 353 adult acute myeloid leukemia (AML) patients and its relationship with several clinical, cytogenetic, and molecular variables. We also studied the expression of 84 genes involved in VEGF signaling in 24 patients. We found that VEGFC expression was higher in AML patients with myelodysplasia-related changes (AML-MRC) than in patients with non-AML-MRC. We also found an association between VEGFC expression and the patient cytogenetic risk group, with those with a worse prognosis having higher VEGFC expression leve…

AdultMale0301 basic medicineCancer ResearchAdolescentAngiogenesisVascular Endothelial Growth Factor CKaplan-Meier EstimateVEGFC expressionYoung Adult03 medical and health sciences0302 clinical medicineKDRBone Marrowhemic and lymphatic diseasesNeuropilin 1Biomarkers TumormedicineNRP1HumansGeneFLT1AgedChromosome AberrationsAcute myeloid leukemiaVascular Endothelial Growth Factor Receptor-1Cell growthbusiness.industryAdult Acute Myeloid LeukemiaHematologyVEGF signalingMiddle AgedPrognosismedicine.diseaseVascular Endothelial Growth Factor Receptor-2Neuropilin-1Leukemia Myeloid AcuteLeukemia030104 developmental biologymedicine.anatomical_structureOncologyVascular endothelial growth factor CMyelodysplastic Syndromes030220 oncology & carcinogenesisCancer researchFemaleBone marrowbusinessLeukemia & Lymphoma
researchProduct

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries

2016

AbstractWe aimed at investigating the distribution and risk of second primary cancers (SPCs) in multiple myeloma (MM) survivors in Germany and Sweden to provide etiological understanding of SPCs and insight into their incidence rates and recording practices. MM patients diagnosed in 1997–2010 at age ≥15 years were selected from the Swedish (nationwide) and 12 German cancer registries. Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compared to risk of the same first cancer in the corresponding background population. Among 18,735 survivors of first MM in Germany and 7,560 in Sweden, overall 752 and 349 SPCs were recorded, respectively. Significantly elevated S…

AdultMale0301 basic medicineOncologyPediatricsmedicine.medical_specialtyTime FactorsMyeloidAdolescentNervous System NeoplasmsPopulationAntineoplastic AgentsArticle03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicinemedicineHumansRegistriesSurvivorseducationMultiple myelomaAgedSwedeneducation.field_of_studyMultidisciplinarybusiness.industryIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseKidney NeoplasmsLeukemia Myeloid AcuteLeukemiaEarly Diagnosis030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisEpidemiology ; Cancer epidemiology ; MyelomaEtiologyFemaleMultiple MyelomabusinessKidney cancerScientific Reports
researchProduct

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

2018

IF 15.132 (2017); International audience; Inherited loci have been found to be associated with risk of chronic lymphocytic leukemia (CLL). A combined polygenic risk score (PRS) of representative single nucleotide polymorphisms (SNPs) from these loci may improve risk prediction over individual SNPs. Herein, we evaluated the association of a PRS with CLL risk and its precursor, monoclonal B-cell lymphocytosis (MBL). We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history (FH) of hematological cancers. For discovery, we pooled genotype data on 41 representative SNPs from 1499 CLL and 2459 controls from the…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyLymphocytosisClinical Trials and ObservationsChronic lymphocytic leukemiaImmunologySingle-nucleotide polymorphism[SDV.CAN]Life Sciences [q-bio]/CancerLymphocytosisPolymorphism Single NucleotideBiochemistry03 medical and health sciences0302 clinical medicineRisk Factorsimmune system diseasesInternal medicinehemic and lymphatic diseasesGenotypeOdds RatiomedicineHumansGenetic Predisposition to Disease10. No inequalityAgedAged 80 and overB-Lymphocytesbusiness.industryConfoundingCell BiologyHematologyOdds ratioMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good health030104 developmental biologyGenetic epidemiologyGenetic Loci030220 oncology & carcinogenesisMonoclonal B-cell lymphocytosisFemalemedicine.symptombusiness
researchProduct

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled…

2019

Background Patients with relapsed or refractory FLT3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia have a poor prognosis, including high frequency of relapse, poorer response to salvage therapy, and shorter overall survival than those with FLT3 wild-type disease. We aimed to assess whether single-agent quizartinib, an oral, highly potent and selective type II FLT3 inhibitor, improves overall survival versus salvage chemotherapy. Methods QuANTUM-R is a randomised, controlled, phase 3 trial done at 152 hospitals and cancer centres in 19 countries. Eligible patients aged 18 years or older with ECOG performance status 0-2 with relapsed or refractory (duration of first …

AdultMale0301 basic medicinemedicine.medical_specialtyPopulationSalvage therapy/Gastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineHumansBenzothiazoleseducationSurvival rateAgedQuizartinibSalvage Therapyeducation.field_of_studybusiness.industryPhenylurea CompoundsMiddle Agedmedicine.diseaseFludarabineSurvival RateTransplantationLeukemia Myeloid AcuteSettore MED/15 - MALATTIE DEL SANGUE030104 developmental biologyfms-Like Tyrosine Kinase 3OncologychemistryTandem Repeat Sequences030220 oncology & carcinogenesisCytarabineFemaleNeoplasm Recurrence LocalbusinessFebrile neutropeniamedicine.drug
researchProduct

Single-Nucleotide Polymorphism Array-Based Karyotyping of Acute Promyelocytic Leukemia

2014

Acute promyelocytic leukemia (APL) is characterized by the t(15;17)(q22;q21), but additional chromosomal abnormalities (ACA) and other rearrangements can contribute in the development of the whole leukemic phenotype. We hypothesized that some ACA not detected by conventional techniques may be informative of the onset of APL. We performed the high-resolution SNP array (SNP-A) 6.0 (Affymetrix) in 48 patients diagnosed with APL on matched diagnosis and remission sample. Forty-six abnormalities were found as an acquired event in 23 patients (48%): 22 duplications, 23 deletions and 1 Copy-Neutral Loss of Heterozygocity (CN-LOH), being a duplication of 8(q24) (23%) and a deletion of 7(q33-qter) (…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyAdolescentOncogene Proteins FusionMicroarrayslcsh:MedicineLoss of HeterozygosityChromosomal translocationBiologyResearch and Analysis MethodsPolymorphism Single NucleotideTranslocation GeneticHematologic Cancers and Related DisordersLoss of heterozygosityYoung AdultLeukemia Promyelocytic AcuteLeukemiasGene duplicationMedicine and Health SciencesmedicineHumanslcsh:ScienceAgedChromosome AberrationsChromosomes Human Pair 15Multidisciplinarylcsh:RBreakpointCytogeneticsBiology and Life SciencesComputational BiologyHematologyMiddle AgedPrognosismedicine.diseaseMolecular biologyLeukemiaBioassays and Physiological AnalysisKaryotypingCancer researchlcsh:QFemaleResearch ArticleChromosomes Human Pair 17SNP arrayPLoS ONE
researchProduct

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

2014

Abstract Differentiation syndrome (DS), formerly known as retinoic acid syndrome, is a relatively common and potentially severe complication seen in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and/or arsenic trioxide. The full-blown syndrome consists of unexplained fever, weight gain, dyspnea with pulmonary infiltrates, pleuropericardial effusion, hypotension, and renal failure. Most measures currently used for management of DS have very little evidence-based support, and therefore, many remain controversial. Despite the lack of evidence supporting DS prophylaxis, several groups have adopted a preventive strategy with corticosteroids, especially for patie…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsPremedicationImmunologyTretinoinBiochemistryArsenicalslaw.inventionchemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcutelawTretinoinInternal medicinemedicineHumansArsenic trioxideIntensive care medicineDexamethasonebusiness.industryOxidesSyndromeCell BiologyHematologymedicine.diseaseIntensive care unitDiscontinuationRetinoic acid syndromeLeukemiachemistryFemalebusinessmedicine.drugBlood
researchProduct

HLA-Cw4 Association with Acute Lymphoblastic Leukaemia in Sicilian Patients

1988

The HLA frequencies of 50 Sicilian patients affected with acute lymphoblastic leukaemia (ALL) were examined. The frequency of Cw4 antigen was significantly increased in patients. Thus results obtained in our homogeneous population confirm in part previous reports suggesting that Cw4-related genetic factors might be involved in the susceptibility to aetiological or pathogenetic mechanisms which play a role in some haematological malignancies.

AdultMaleAdolescentPopulationHLA-C AntigensHuman leukocyte antigenPathogenesisAntigenHLA AntigensAcute lymphocytic leukemiamedicineHumanseducationSicilyeducation.field_of_studybusiness.industryHematologyGeneral Medicinemedicine.diseaseLeukemia LymphoidLeukemiaChild PreschoolImmunologyEtiologyLymphoblastic leukaemiaFemalebusinessVox Sanguinis
researchProduct

Bone marrow after autologous blood stem cell transplantation and total body irradiation: magnetic resonance and chemical shift imaging.

1993

Magnetic resonance studies of the lumbar, pelvic, and femoral bone marrow were performed in 10 patients after autologous blood stem cell transplantation, including total body irradiation and myeloablative chemotherapy. The posttreatment interval varied between 2 and 6 yr. The appearance on T1-weighted images and the quantitative data obtained from chemical shift imaging (relative fat signal) were compared to 10 age-matched healthy volunteers. The classification of the T1-weighted images yielded no significant differences between the two groups. Chemical shift imaging by determination of the relative fat signal was able to detect a significant fatty replacement of the patients' lumbar (p < .…

AdultMaleAdolescentmedicine.medical_treatmentBiomedical EngineeringBiophysicsBlood cellLumbarBone MarrowmedicineHumansRadiology Nuclear Medicine and imagingFemurChildPelvic BonesChemotherapyLeukemiaLumbar Vertebraemedicine.diagnostic_testChemistrybusiness.industryHematopoietic Stem Cell TransplantationMagnetic resonance imagingTotal body irradiationMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingTransplantationmedicine.anatomical_structureAcute DiseaseFemaleBone marrowStem cellNuclear medicinebusinessWhole-Body IrradiationMagnetic resonance imaging
researchProduct

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study

2017

GREEN (NCT01905943) is a non-randomized, open-label phase IIIb study investigating obinutuzumab alone or plus chemotherapy in chronic lymphocytic leukemia (CLL). We report a preplanned subgroup analysis of 158 previously untreated CLL patients receiving obinutuzumab–bendamustine (G-B). Patients received six 28-day cycles (C) of G-B: obinutuzumab day (D)1/D2 of C1 (25 mg D1/975 mg D2), 1000 mg D8 and D15 of C1, and D1 of C2–6; and bendamustine 70/90 mg/m2 D1 and D2 of C1–6. The primary endpoint was safety/tolerability. Grade ≥3 adverse events (AEs) occurred in 82.3% of patients, including neutropenia (49.4%), thrombocytopenia (12.0%) and febrile neutropenia (10.8%). Serious AEs included neut…

AdultMaleBendamustineCancer Researchmedicine.medical_specialtyNeoplasm ResidualNeutropeniaAntibodies Monoclonal HumanizedGastroenterologyArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicineObinutuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBendamustine HydrochlorideHumansSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryRemission InductionHematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellMinimal residual diseaseSurvival RateTumor lysis syndromeOncologyTolerabilitychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRituximabbusinessFebrile neutropeniaFollow-Up Studies030215 immunologymedicine.drugLeukemia
researchProduct

The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammatio…

2013

Macrophages reside in tissues infiltrated by chronic lymphocytic leukemia B cells and the extent of infiltration is associated with adverse prognostic factors. We studied blood monocyte population by flow cytometry and whole-genome microarrays. A mixed lymphocyte reaction was performed to evaluate proliferation of T cells in contact with monocytes from patients and normal donors. Migration and gene modulation in normal monocytes cultured with CLL cells were also evaluated. The absolute number of monocytes increased in chronic lymphocytic leukemia patients compared to the number in normal controls (792 +/- 86 cells/mu L versus 485 +/- 46 cells/mL, P=0.003). Higher numbers of non-classical CD…

AdultMaleCD14Chronic lymphocytic leukemiaPhagocytosisPopulationDown-RegulationInflammationMICROENVIRONMENTCD16BiologyTUMOR-ASSOCIATED MACROPHAGES; TIE2-EXPRESSING MONOCYTES; MICROENVIRONMENT; CLLMonocytesImmune systemPhagocytosismedicineHumanseducationCells CulturedAgedAged 80 and overInflammationeducation.field_of_studyMonocyteGene Expression ProfilingHematologyMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-CellTIE2-EXPRESSING MONOCYTESGene Expression Regulation NeoplasticChronic Lymphocytic Leukemia; Monocyte; microenvironmentTUMOR-ASSOCIATED MACROPHAGESmedicine.anatomical_structureImmunologyFemalemedicine.symptomLymphocyte Culture Test MixedOriginal Articles and Brief ReportsCLLHaematologica
researchProduct